lysine-specific demethylase 1 inhibitor incb059872
lysine-specific demethylase 1 inhibitor incb059872: 3 clinical trials tracked.
lysine-specific demethylase 1 inhibitor incb059872 evidence translation
What we can confirm
3 tracked trials
What it means
What to watch
Prepared research question
What is verified about lysine-specific demethylase 1 inhibitor incb059872, and what remains unknown?
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trial Registry Records (3)
An Open-Label Phase 1b Study of the Safety, Tolerability, and Preliminary Antitumor Activity of INCB059872 in Participants With Relapsed or Refractory Ewing Sarcoma
Primary endpoint: Number of adverse events
A Phase 1/2 Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Azacitidine in Combination With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors and Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Stage IV Microsatellite-Stable Colorectal Cancer (ECHO-206)
Primary endpoint: Part 1 and 2 : Number of Participants With Treatment Emergent Adverse Events
A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion, Safety and Tolerability Study of INCB059872 in Subjects With Advanced Malignancies
Primary endpoint: Number of Participants Receiving INCB059872 Monotherapy With Any Treatment-emergent Adverse Event (TEAE)